<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - DOXORUBICIN HYDROCHLORIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>DOXORUBICIN HYDROCHLORIDE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Acute leukaemias</span>,
                <span class="indication">Hodgkin's lymphoma</span>,
                <span class="indication">Non-Hodgkin's lymphoma</span>,
                <span class="indication">Some solid tumours including breast cancer</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult product literature).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Some papillary bladder tumours (bladder instillation)</span>,
                <span class="indication">Recurrent superficial bladder tumours (bladder instillation)</span>,
                <span class="indication">Transitional cell carcinoma (bladder instillation)</span>,
                <span class="indication">Carcinoma in situ (bladder instillation)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravesical instillation</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult product literature).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid (teratogenic and toxic in <i>animal</i> studies).</p>
            </section>
            <section class="generalInformation">
              <p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Reduce dose according to bilirubin concentration&#8212;consult product literature or local treatment protocol for details.</p>
            </section>
            <section class="generalInformation">
              <p>Avoid in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Consult product literature in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Consult product literature</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Dehydration, diarrhoea, red colouration of the urine,
              </p>
              <p>
                <strong>uncommon:</strong> Supraventricular tachycardia (related to drug administration),
              </p>
              <p>
                <strong>notKnown:</strong> Alopecia, bone-marrow suppression, cardiomyopathy (with higher cumulative doses), consult product literature, extravasation, heart failure (potentially fatal), hyperuricaemia, nausea, oral mucositis, renal damage, thromboembolism, tumour lysis syndrome, vomiting,
              </p>
        
        
            <section class="advice">
                <h3>Extravasation</h3>
              <p>Extravasation can cause severe tissue necrosis.</p>
            </section>
            <section class="advice">
                <h3>Cardiomyopathy</h3>
              <p>Higher cumulative doses are associated with cardiomyopathy and it is usual to limit total cumulative doses to 450&#8239;mg/m<sup>2</sup> because symptomatic and potentially fatal heart failure is common above this dose.</p>
            </section>
            <section class="advice">
                <h3>Cardiotoxic</h3>
              <p>Some evidence suggests that weekly low-dose administration may be less cardiotoxic.</p>
            </section>
            <section class="advice">
                <h3>Liposomal formulations</h3>
              <p>
            <i>Liposomal</i> formulations of doxorubicin may reduce the incidence of cardiotoxicity and lower the potential for local necrosis, but infusion reactions, sometimes severe, may occur. Hand-foot syndrome (painful, macular reddening skin eruptions) occurs commonly with liposomal doxorubicin and may be dose limiting. It can occur after 2&#8211;3 treatment cycles and may be prevented by cooling hands and feet and avoiding socks, gloves, or tight-fitting footwear for 4&#8211;7 days after treatment.</p>
            </section>
            <section class="advice">
                <h3>Elevated bilirubin concentration</h3>
              <p>Doxorubicin is largely excreted in the bile and an elevated bilirubin concentration is an indication for reducing the dose.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>
            <i>Conventional</i> doxorubicin is given by injection into a fast-running infusion, commonly at 21-day intervals.</p>
            </section>
      </section>


      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA91</h3>
              <p outputclass="title">Paclitaxel, pegylated liposomal doxorubicin, and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005)</p> <p>Paclitaxel, combined with a platinum compound (carboplatin or cisplatin), is an option for advanced cancer that relapses 6 months or more after completing initial platinum-based chemotherapy. Paclitaxel alone is an option for advanced ovarian cancer that does not respond to, or relapses within 6 months of completing initial platinum-based chemotherapy.</p> <p>Pegylated liposomal doxorubicin is an option for advanced ovarian cancer that does not respond to, or relapses within 12 months of completing initial platinum-based chemotherapy.</p> <p>Paclitaxel alone or pegylated liposomal doxorubicin are options for advanced ovarian cancer in patients who are allergic to platinum compounds. Topotecan alone is an option only for advanced ovarian cancer that does not respond to, or relapses within 6 months of completing initial platinum-based chemotherapy or in those allergic to platinum compounds<i> and</i> for whom paclitaxel alone or pegylated liposomal doxorubicin are inappropriate.</p><xref format="html" href="http://www.nice.org.uk/TA91">www.nice.org.uk/TA91</xref>
                <a href="http://www.nice.org.uk/TA91" target="_blank">www.nice.org.uk/TA91</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cardiac disease
          </li>
          <li>
            caution in handling&#8212;irritant to tissues
          </li>
          <li>
            consult product literature
          </li>
          <li>
            elderly
          </li>
          <li>
            hypertension
          </li>
          <li>
            previous myocardial irradiation
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended). Manufacturer advises effective contraception during and for at least 6 months after treatment in men or women.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Patients should be assessed before treatment, by echocardiography. Cardiac monitoring during treatment may assist in determining safe dosage.</p>
            </section>
      </section>


      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Doxorubicin is available as both <i>conventional</i> and <i>liposomal</i> formulations. The different formulations vary in their licensed indications, pharmacokinetics, dosage and administration, and are not interchangeable.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of DOXORUBICIN HYDROCHLORIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            solution for infusion,

            <div id="PHP76251"><a href="../medicinalForm/PHP76251.html" data-target="#PHP76251" data-action="load">Solution for injection</a></div>
            <div id="PHP76244"><a href="../medicinalForm/PHP76244.html" data-target="#PHP76244" data-action="load">Powder for solution for injection</a></div>
            <div id="PHP76266"><a href="../medicinalForm/PHP76266.html" data-target="#PHP76266" data-action="load">Solution for infusion</a></div>
            <div id="PHP76259"><a href="../medicinalForm/PHP76259.html" data-target="#PHP76259" data-action="load">Powder and solvent for suspension for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
